Drugs / A27.15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003082 | Dec 1997 → Feb 2001 | leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm +1 | University of Arizona | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A27.15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003082 ↗ |
| Action | Inhibit | “Transferrin receptor protein 1 antagonist” CHEMBL2109494 ↗ |
| Modality | Monoclonal antibody | “Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15” NCT00003082 ↗ |
| Route | Intravenous | “Patients receive antitransferrin antibody A27.15 IV over 4 hours.” NCT00003082 ↗ |
| Target | TFRC | “Transferrin receptor protein 1 antagonist” CHEMBL2109494 ↗ |